Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish ...
Novo Nordisk’s (NVO) (OTCPK:NONOF) contract with Swiss medical device maker Ypsomed (OTCPK:YPHDF) includes a deal to supply ...
If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. To calculate this metric for Ypsomed Holding, this is the ...
GlobalData on MSN5d
“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirlNovo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.
The latest health news highlights FDA's approval of BridgeBio's drug for a rare heart condition, cancer features in healthy ...
Medical technology manufacturer plans to divest diabetes products business / Focus on injection systems © 2001-2024 Plasteurope.com | Imprint | Privacy | Cookie settings ...
Novo Nordisk’s (NVO) (OTCPK:NONOF) contract with Swiss medical device maker Ypsomed (OTCPK:YPHDF) includes a deal to supply injection pens for Danish drugmaker’s next-gen obesity therapy ...
0.13 = CHF87m ÷ (CHF1.2b - CHF513m) (Based on the trailing twelve months to September 2024). So, Ypsomed Holding has an ROCE of 13%. That's a pretty standard return and it's in line with the industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback